HTG Molecular Diagnostics Announces Proposed Public Offering Of Common Stock -

HTG Molecular Diagnostics Announces Proposed Public Offering Of Common Stock

Jan 16, 2018Jeremy ParkinsonFinance0

TUCSON, Ariz., Jan. 16, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that it intends to offer and sell, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. All of the shares are being offered by HTG. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners LLC and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. LifeSci Capital LLC is acting as co-manager for the offering. HTG expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock.

The shares of common stock described above are being offered by HTG pursuant to a shelf registration statement filed by HTG with the Securities and Exchange Commission (SEC) that was declared effective on April 6, 2017. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808‑7525 ext. 6132, or by email at [email protected], or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by telephone at (212) 829-7122, or by email at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.